Bendamustine a safe alternative to fludarabine/cyclophosphamide lymphodepletion for axi-cel therapy in aggressive BCLSeptember 22, 2023B Cell Lymphoma
Concurrent MYC overexpression and TP53/p53 alterations indicative of poor prognosis in MCLSeptember 22, 2023B Cell Lymphoma
PI3Kδ inhibitor parsaclisib shows promise in relapsed or refractory follicular lymphomaSeptember 22, 2023B Cell Lymphoma
Tisagenlecleucel vs conventional treatment improves survival in DLBCLSeptember 22, 2023B Cell Lymphoma
CAR-HEMATOTOX score identifies patients at high risk for poor outcomes following brexu-cel infusion for MCLSeptember 22, 2023B Cell Lymphoma
Loncastuximab tesirine shows long-term efficacy in relapsed or refractory DLBCLSeptember 22, 2023B Cell Lymphoma
Parsaclisib a promising treatment option in BTKi-naive relapsed or refractory MCLSeptember 22, 2023B Cell Lymphoma
Lymphoma specialist to lead MD Anderson’s cancer medicine divisionAugust 22, 2023B Cell LymphomaMantle Cell Lymphoma
Meta-analysis shows geriatric nutritional risk index to be a strong predictor of survival in DLBCLAugust 19, 2023B Cell Lymphoma
Pre-treatment serum IL-6 and IL-10 levels predict prognosis and treatment response in newly diagnosed DLBCLAugust 19, 2023B Cell Lymphoma
Bendamustine plus rituximab improves survival over rituximab plus CVP or CHOP in indolent B-cell lymphomaAugust 19, 2023B Cell Lymphoma
Lenalidomide plus R-ESHAP a feasible salvage regimen in relapsed or refractory DLBCLAugust 19, 2023B Cell Lymphoma
